Wedbush Has Positive Estimate for CMPX FY2024 Earnings

Compass Therapeutics, Inc. (NASDAQ:CMPX) – Analysts at Wedbush raised their FY2024 EPS estimates for Compass Therapeutics in a note issued to investors on Tuesday, November 12th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings of ($0.32) per share for the year, up from their previous estimate of ($0.39). Wedbush currently has a “Outperform” rating and a $8.00 target price on the stock. The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.42) per share. Wedbush also issued estimates for Compass Therapeutics’ Q4 2024 earnings at ($0.07) EPS, Q1 2025 earnings at ($0.07) EPS, Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.28) EPS, FY2026 earnings at $0.31 EPS and FY2028 earnings at $1.76 EPS.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.03.

A number of other research firms have also issued reports on CMPX. LADENBURG THALM/SH SH raised shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price target for the company in a research report on Monday, September 16th. Leerink Partnrs cut shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Compass Therapeutics in a report on Monday, November 11th. Finally, Leerink Partners lowered Compass Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $5.00 to $4.00 in a research note on Friday. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, Compass Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $6.75.

Compass Therapeutics Stock Down 13.2 %

Compass Therapeutics stock opened at $1.38 on Friday. The stock has a 50-day moving average price of $1.75 and a 200 day moving average price of $1.42. The company has a market capitalization of $189.87 million, a price-to-earnings ratio of -3.73 and a beta of 0.92. Compass Therapeutics has a 52 week low of $0.77 and a 52 week high of $2.34.

Institutional Trading of Compass Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Rovin Capital UT ADV acquired a new position in shares of Compass Therapeutics in the third quarter worth about $25,000. Intech Investment Management LLC purchased a new position in shares of Compass Therapeutics in the 3rd quarter valued at about $30,000. XTX Topco Ltd acquired a new position in Compass Therapeutics in the 3rd quarter worth about $37,000. SG Americas Securities LLC boosted its position in Compass Therapeutics by 16.6% during the third quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock worth $71,000 after purchasing an additional 5,515 shares in the last quarter. Finally, Bleakley Financial Group LLC acquired a new stake in Compass Therapeutics in the first quarter valued at approximately $80,000. 68.43% of the stock is owned by hedge funds and other institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.